Grants & Funding



Now accepting applications.

CARRA is pleased to announce that through a partnership with Brigham and Women’s Hospital and Harvard Medical School we are able to select one CARRA member to participate in the VERITY/Brigham Course in Rheumatology Clinical Research in Boston, MA at Brigham and Women’s Hospital.

2020 VERITY/Brigham Course in Rheumatology Clinical Research

VERITY (Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics) is a NIAMS-funded P30 research program awarded to Brigham and Women’s Hospital. The next VERITY course will be Tuesday, May 12, 2020 to Friday, May 15, 2020, in Boston, MA. The course is aimed at clinical investigators pursuing rheumatic disease epidemiologic and patient-oriented research. Course attendees will consist of early-stage (typically residents, fellows, or junior faculty) investigators pursuing clinical/patient-oriented/epidemiologic research studies in rheumatic and musculoskeletal diseases. Attendees will develop or refine a research protocol or specific aims for a grant proposal during the course. Tuition is free but travel and lodging should be funded by the applicant’s program.

CARRA members have a chance to be selected for a travel award funded by NIAMS. Criteria for the award include being an active member of CARRA and complete submission of the VERITY course application before the deadline. CARRA will then select a member to receive the VERITY course travel award.

The previous VERITY course was attended by 15 trainees and junior faculty from across the US, including 7 pediatric rheumatologists. The VERITY faculty included Brigham and Women’s Hospital faculty as well as pediatric rheumatologists including Dr. Brian Feldman (Toronto Sick Kids), Dr. MaryBeth Son (Boston Children’s Hospital), and Dr. Peter Nigrovic (Brigham and Women’s Hospital and Boston Children’s Hospital).

CARRA member and previous VERITY course attendee Dr. Rebecca Trachtman (Mount Sinai Kravis Children’s Hospital) said, “I left this course with a much better sense of the path that I want to follow going forward as a young investigator, as well as the steps that I need to take in order to get to where I want to be. I was able to meet faculty members who were willing to be mentors, and with whom I am sure I will continue to work throughout my career. I highly recommend applying to attend for anyone who is interested in pursuing an academic research career in rheumatology”.

The course is directed by Dr. Jeffrey Sparks and Dr. Daniel Solomon of Brigham and Women’s Hospital. To learn more about the 2020 VERITY course, including application materials, deadlines, please visit or email [email protected].

Travel Support:

The chosen applicant will have their hotel paid for directly by the course organizers and reimbursement of travel expenses to participate in the 6 day course. Course organizers will coordinate travel arrangements with the chosen applicant. Funding for this travel support is provided by NIAMS.


To be eligible for the CARRA opening you must have renewed your CARRA membership and meet the VERITY/Brigham Course in Clinical Research eligibility guidelines:

  • The course is for early-stage (typically fellows or junior faculty) investigators pursuing clinical/patient-oriented/epidemiologic research studies in rheumatic and musculoskeletal diseases.
  • The course is aimed at applicants who are not yet independent, but are currently performing or have performed research investigations.
  • Successful applicants will typically hold the academic rank of fellow, Instructor, or Assistant Professor and should be actively performing mentored clinical/patient-oriented/epidemiologic/transitional research studies.
  • Applicants holding independent funding (R01 or equivalent) are not eligible.


For questions about the Clinical Research Course, please contact the VERITY program coordinator, Jackie Stratton at [email protected].

For questions about CARRA’s selection process for this program, contact CARRA Director of Administration, Brian Mondragón Jones at [email protected].